COVID-19: Russian RDIF invests in Mirai Genomics in Japan: Life Pad test kit
COVID-19:
On March 19, the Russian Federation Direct Investment Fund (RDIF) announced a place release on its official website.
RDIF invested in Medpromresurs to produce a COVID-19 detection kit.
Medpromresurs:
Medpromresurs’ development partner is Mirai Genomics of Yokohama, Japan.
Signed a cooperation agreement with the Republic of Tatarstan at the Eastern Economic Forum in Vladivostok in September 2019.
Republic of Tatarstan: Mirai Genomics
Mirai Genomics will manufacture a Life Pad test kit and make an investment of 2.5 billion rubles in the Republic of Tatarstan.
This time, a new coronavirus test kit developed and manufactured in Russia uses Mirai Genomics’ SmartAmp technology.
Tests with the same accuracy as the PCR method can be performed in a short time of up to 30 minutes.
JBpress（Japan Business Press）
https://jbpress.ismedia.jp/articles/-/59919?page=5
RDIF Promises 5,000 Coronavirus Test Kits a Day in New Project
RDIF and Japan’s Mirai Genomics
have developed a new diagnostic system for detecting the virus, which can be used both at static laboratories and at unique portable mini-laboratories.
The system is using the SmartAmp method, enabling express diagnostics within up to 30 minutes.
It has already received approval from the Russian healthcare watchdog.
Russia Business Today
Russia’s RDIF to invest in coronavirus tests developer Medpromresurs
MOSCOW —
The Russian Direct Investment Fund (RDIF) said on Thursday it will invest in Medpromresurs, a Russian company that is currently developing coronavirus tests.
RDIF said
that its partners in Medpromresurs, established to focus on a new Russian-Japanese diagnostic system for coronavirus,
are Japan’s К.R. Mirai Genomics and two other Russian firms.
The London Free Press
Mirai Genomics